Key Laboratory of Freshwater Fishery Germplasm Resources, Ministry of Agriculture, Shanghai Ocean University, Shanghai 201306, People's Republic of China.
BMC Vet Res. 2013 Jun 25;9:126. doi: 10.1186/1746-6148-9-126.
Antibiotic resistance has become a serious global problem and is steadily increasing worldwide in almost every bacterial species treated with antibiotics. In aquaculture, the therapeutic options for the treatment of A. hydrophila infection were only limited to several antibiotics, which contributed for the fast-speed emergence of drug tolerance. Accordingly, the aim of this study was to establish a medication regimen to prevent drug resistant bacteria. To determine a rational therapeutic guideline, integrated pharmacodynamics and pharmacokinetics parameters were based to predict dose and dosage interval of enrofloxacin in grass carp Ctenopharyngodon idella infected by a field-isolated A. hydrophila strain.
The pathogenic A. hydrophila strain (AH10) in grass carp was identified and found to be sensitive to enrofloxacin. The mutant selection window (MSW) of enrofloxacin on isolate AH10 was determined to be 0.5-3 μg/mL based on the mutant prevention concentration (MPC) and minimum inhibitory concentration (MIC) value. By using high-performance liquid chromatography (HPLC) system, the Pharmacokinetic (PK) parameters of enrofloxacin and its metabolite ciprofloxacin in grass carp were monitored after a single oral gavage of 10, 20, 30 μg enrofloxacin per g body weight. Dosing of 30 μg/g resulted in serum maximum concentration (Cmax) of 7.151 μg/mL, and concentration in serum was above MPC till 24 h post the single dose. Once-daily dosing of 30 μg/g was determined to be the rational choice for controlling AH10 infection and preventing mutant selection in grass carp. Data of mean residue time (MRT) and body clearance (CLz) indicated that both enrofloxacin and its metabolite ciprofloxacin present similar eliminating rate and pattern in serum, muscle and liver. A withdraw time of more than 32 d was suggested based on the drug eliminating rate and pharmacokinetic model described by a polyexponential equation.
Based on integrated PK/PD parameters (AUC/MIC, Cmax/MIC, and T>MPC), the results of this study established a principle, for the first time, on drawing accurate dosing guideline for pharmacotherapy against A. hydrophila strain (AH10) for prevention of drug-resistant mutants. Our approach in combining PK data with PD parameters (including MPC and MSW) was the new effort in aquaculture to face the challenge of drug resistance by drawing a specific dosage guideline of antibiotics.
抗生素耐药性已成为一个严重的全球问题,几乎在所有使用抗生素治疗的细菌物种中,耐药性都在全球范围内稳步增加。在水产养殖中,用于治疗嗜水气单胞菌感染的治疗选择仅限于几种抗生素,这导致了耐药性的快速出现。因此,本研究的目的是建立一种预防耐药菌的药物治疗方案。为了确定合理的治疗指南,本研究基于药效学和药代动力学参数来预测恩诺沙星在草鱼(Ctenopharyngodon idella)感染分离的嗜水气单胞菌菌株时的剂量和给药间隔。
从草鱼中分离出的致病性嗜水气单胞菌(AH10)菌株被鉴定,并发现对恩诺沙星敏感。根据突变预防浓度(MPC)和最小抑菌浓度(MIC)值,恩诺沙星对分离株 AH10 的突变选择窗(MSW)确定为 0.5-3μg/mL。通过使用高效液相色谱(HPLC)系统,监测了草鱼单次口服 10、20、30μg/ g 体重的恩诺沙星后的恩诺沙星及其代谢物环丙沙星的药代动力学(PK)参数。30μg/g 的剂量导致血清最大浓度(Cmax)为 7.151μg/mL,单次剂量后 24 小时内血清浓度仍高于 MPC。确定每日一次 30μg/g 的剂量是控制草鱼嗜水气单胞菌感染和预防突变选择的合理选择。平均残留时间(MRT)和体清除率(CLz)的数据表明,恩诺沙星及其代谢物环丙沙星在血清、肌肉和肝脏中的消除率和模式相似。根据药物消除率和多指数方程描述的药代动力学模型,建议停药时间超过 32d。
基于综合的 PK/PD 参数(AUC/MIC、Cmax/MIC 和 T>MPC),本研究首次为针对嗜水气单胞菌(AH10)菌株的抗菌治疗建立了准确的给药指南,以预防耐药突变。我们将 PK 数据与 PD 参数(包括 MPC 和 MSW)相结合的方法是水产养殖领域应对耐药性挑战的新尝试,通过制定特定的抗生素剂量指南来解决这一问题。